ZYBERNO
Stock Report
Updated Sep 1, 2026

Ernexa Therapeutics Inc. (ERNA)

Healthcare • NASDAQ

$4.47

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
25.0/100
POOR BUSINESS
Ernexa Therapeutics Inc. (ERNA) scores 25/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-305.9%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.22x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-803.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Ernexa Therapeutics Inc. (ERNA) stock report — Zyberno Score 25/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ERNA generated -$8.34M in Owner Earnings. Reinvestment rate: -2.2%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.47
Market Cap:$5.29M

Valuation Multiples (3)

P/B Ratio:1.65x
P/S Ratio:9.09x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$609.01K

Price Action & Momentum (1)

% of 52-Week High:6.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-169.9%
Reinvestment Rate:-2.2%
Fundamental Growth Rate (g):17.9%

Margin Analysis (1)

Ebitda Margin:-2,330.1%

Yield Metrics (2)

Earnings Yield:-$277.05
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-230.9%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.01x
Quick Ratio:2.01x
Cash Ratio:1.71x

Leverage Analysis (3)

Debt To Equity Ttm:0.22x
Debt-to-Equity Ratio:0.22x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:2,962,000.00
Cash And Cash Equivalents:5,028,000.00
Long Term Debt:$182.00K
Net Debt:-$4.68M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $582.00K
Linear Growth: -50.0%
📊 Click to view full ERNA Revenue analysis & methodology →
Cost Of Revenue Ttm:$96.00K

Profitability Breakdown (2)

$486.00K-$13.78M

Bottom Line Performance (3)

-$12.26M
Income Before Tax:-$12.35M
Ebitda Ttm:-13,561,000.00

Operating Expenses (5)

Operating Expenses:13,782,000.00
R And D Expense:6,418,000.00
Sga Expense:5,320,000.00
Income Tax Expense:-$93.00K
Interest Expense:-2,584,000.00

Expense Ratios (3)

R And D To Revenue Percentage:641,800.0%
Sga To Revenue Percentage:532,000.0%
Ebitda Margin:-2,330.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$6.32M
Current Assets:$5.89M
Ppe Net:82,000.00
Goodwill:2,044,000.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,115,000.00
Current Liabilities:2,932,000.00
Long Term Debt:$182.00K
Short Term Debt:$167.00K

Equity & Capital (3)

Equity:$3.20M
Retained Earnings:-$255.16M
Common Stock:150,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,375,000.00

Special Items (2)

Contract Liabilities:5,335,000.00
Stock Based Compensation:320,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$7.22M-$8.57M

Investment Activities (1)

Investing Cash Flow:-$2.00K

Financing Activities (3)

Financing Cash Flow:$9.56M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:10,480,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:221,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-11.83
-$11.83
Earnings Per Share Ttm:-$10.36

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.49
Operating Cash Flow Per Share:-$13.39

Book Value & Capital (2)

Book Value Per Share:$2.70
Cash Per Share:4.25

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.08x
Working Capital Turnover Ttm:0.20x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:5,227.86
Cash Conversion Cycle:-7,225.86
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$8.34M

Damodaran Growth Analysis (2)

Reinvestment Rate:-2.2%
Fundamental Growth Rate (g):17.9%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-26.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:ERNA
Company Name:Ernexa Therapeutics Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.18M
Shares Outstanding Basic:1.18M
Shares Outstanding Diluted:1.18M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 16:42:54 UTC
Data Timestamp:2026-08-21T21:08:19.663915
Scroll to Top